2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 714

Baseline MRI and CRP As Predictors of Response to Etanercept in the Management of Patients with Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
Abstract Number: 39

Baseline Obesity and Subsequent Weight Loss Are Independently Associated with Cardiovascular Mortality in Established Rheumatoid Arthritis
Abstract Number: 2938

Baseline Predictors of Remission and Low Disease Activity Using Recently Defined International Criteria in a Multi-Center Lupus Registry Cohort
Abstract Number: 545

Baseline Serum Soluble Interleukin–2 Receptor Alpha (sIL–2Rα) Levels Increased as Intervals Decreased from Cohort Entry to Onset of Incident Rheumatoid Arthritis (pre–RA), not Observed in Matched Control (CN) Subjects
Abstract Number: 214

Basic Calcium Phosphate Crystal Interactions with Tenocytes: An in Vitro Model of Calcific Tendinitis
Abstract Number: 8

Bay 11-7085 Induces Glucocorticoid Receptor Activation and Autophagy to Initiate Human Synovial Fibroblast Cell Death
Abstract Number: 2309

Bedtime, Rapidly Absorbed Sublingual Cyclobenzaprine (TNX-102 SL) for the Treatment of Fibromyalgia: Results of a Phase 2b Randomized, Double-Blind, Placebo-Controlled Study
Abstract Number: 743

Behavior of Complement Levels and Risk of Organ Involvement in SLE Patients
Abstract Number: 750

Belimumab for Systemic Lupus Erythematosus: A Cochrane Systematic Review and Meta-Analysis
Abstract Number: 735

Belimumab Reduces the Frequency of Flares and Prevents Damage Progression in SLE Patients: Experience in a Clinical Practice Setting
Abstract Number: 822

Beneficial Effect of Botulinum Toxin-a on Raynaud’s Phenomenon in Japanese Patients with Systemic Sclerosis: A Prospective, Open-Label Trial
Abstract Number: 475

Benefits of Achieving Comprehensive Disease Control (CDC) in Patients with Rheumatoid Arthritis: Evidence from the Corrona Registry
Abstract Number: 325

Best Performing Definition of Accelerated Knee Osteoarthritis
Abstract Number: 1602

Beta Cells Function and Insulin Resistance during Tocilizumab Treatment in Non-Diabetic RA Patients: Results from a Single-Center Study
Abstract Number: 2779

Better Drug Survival of Non-TNFi Compared to TNFi Biologics after Non-TNFi Failure in RA Patients: A Single Center Experience

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].